Gapping down
In reaction to disappointing earnings/guidance:
- NLS -41%, CASA -31.8%, PRGS -11.1%, NFLX -3.1%, RF -2.6%, AXP -2.3%, FHN -1.6%, TIF -0.6%
Other news:
- LXRX -24.7% (FDA AdCom votes 8-8 over whether to support sotagliflozin as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes mellitus)
- TSLA -6.9% (company to cut 7% of workforce, warns that the road ahead is 'very difficult', says preliminary figures suggest Q4 generated GAAP profit, but was less than that from Q3)
- KIN -5.7% (proposed public offering of common stock)
- CVRR -4.8% (CVR Energy reports exercise of right to purchase common units of CVR Refining)
- LLY -2.4% (reports results of Phase 3 soft tissue sarcoma study of LARTRUVO -- study did not meet primary endpoints)
- SNY -0.7% (FDA AdCom votes 8-8 over whether to support sotagliflozin as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes mellitus)
Analyst comments:
- SIG -1.5% (downgraded to Sell from Neutral at Citigroup)
- PPG -0.4% (downgraded to Neutral from Overweight at JP Morgan)
